The FDA last week approved Regeneron Pharmaceuticals, Inc. and Sanofi’s Libtayo for the treatment of advanced basal cell carcinoma (BCC) that has not responded to previous treatment in some patients. The anti-PD-1 inhibitor is the first immunotherapy drug approved to treat BCC. Libtayo was approved for the treatment of metastatic cutaneous squamous cell carcinoma in September 2018, and currently holds preferred placement under the pharmacy benefit for 9% of all covered lives. Libtayo is not covered for 21% of lives.
SOURCE: MMIT Analytics, as of 2/11/21